What it is
“40 Hz” usually means a sound that pulses 40 times a second. It is sold as a beat, a binaural beat or a pulse inside music, often with the word “gamma” on the thumbnail. Gamma is the name for brain activity in this speed range.
What the research says
The 40 Hz idea comes from Alzheimer’s research. In a 2024 study at MIT, mice exposed to 40 Hz light and sound showed changes in the brain related to Alzheimer’s disease [1]. That was in mice. A 2023 study found that 40 Hz light did not drive matching brain activity in people with Alzheimer’s [2]. A larger trial in patients, using light plus sound together, has finished enrolling [3].
None of this research tested focus, attention or ADHD. It also mostly used light and sound together, not audio alone. So there is no evidence that 40 Hz audio helps you focus. There is also no evidence that it doesn’t. It simply hasn’t been studied for that.
Who it may help, and who it may not
If you like how a 40 Hz track sounds, there is no known harm in listening. Just know that anything you notice is your own experience, and the research behind the label is about something else.
How we use it in our sessions
We don’t use 40 Hz in our sessions. We know many people search for it, and we considered it. We chose to put our pulses where there is at least some research on attention, such as the 16 Hz pulse described on our amplitude modulation page.
This is a focus tool, not a treatment. If you are looking into ADHD care, please talk to your clinician.
Sources
- Murdock et al. (2024), Nature. 40 Hz light and sound stimulation in mice with Alzheimer’s disease. Summary from MIT: https://news.mit.edu/2024/how-sensory-gamma-rhythm-stimulation-clears-amyloid-alzheimers-mice-0307
- Soula et al. (2023). 40 Hz light did not drive matching brain activity in Alzheimer’s patients, a failed replication. https://alzforum.org/papers/forty-hertz-light-stimulation-does-not-entrain-native-gamma-oscillations-alzheimers-disease
- Cognito Therapeutics HOPE trial (light plus sound in Alzheimer’s patients), enrolment news. https://www.medicaleconomics.com/view/cognito-therapeutics-completes-enrollment-in-landmark-alzheimer-s-trial